Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Fipravirimat with Darunavir/Ritonavir and Etravirine in Healthy Adults
NCT04630002Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fipravirimat in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval at Steady State at Day 26 and Maximum Observed Concentration at Day 26. Started Oct 2020; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04630002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630002.